Pieter Cullis & Jay Julkarni @ Next-Generation Nanomedicine symposium
We're thrilled to announce that NTx Co-Founder Pieter Cullis will be keynote speaker at the Next-Generation Nanomedicine symposium.
Christian Kastrup presents @ MHSRS
Co-founder Dr. Christian Kastrup is presenting on Aug 15 in the Military Health System Research Symposium.
Pieter Cullis appointed to the Order of British Columbia
NTx Co-Founder Dr. Pieter Cullis has been appointed to the Order of BC, the province's highest honour.
Christian Kastrup presents guest lecture @ BCCHR
NTx co-founder Dr. Christian Kastrup will deliver a guest lecture at BC Children's Hospital Research Institute on August 2nd.
Dr. Pieter Cullis elected a Fellow of the Royal Society
NTx Co-Founder Dr. Pieter Cullis has been elected Fellow of the prestigious UK Royal Society.
Pieter Cullis speaks @ Annual RNATx Conference 2023
NTx Co-founder Pieter Cullis is a keynote speaker (with colleague Katalin Karikó) at the 5th Annual RNATx Conference, 21-23 June 2023 in Worcester, MA.
Kevin An @ CBS 2023 Annual Meeting in Halifax
NTx team member Kevin An will be talking about NanoVation's lcLNP at the CBS Annual Meeting in Halifax this Thursday afternoon.
Arpan Desai @ Cambridge Wide Open Day 2023
Arpan Desai will present an “Introduction to mRNA Based Therapeutics for COVID and Beyond” as part of Cambridge Wide Open Day on June 14.
Molly Stevens & Arpan Desai @ Nanomed Europe 23
Event Next week at Nanomed Europe 23, NTx will be well represented. Molly Stevens, NTx UK Board Member and ...
CSO Jayesh Kulkarni @ HLI Seminar Series at UBC
NTx CSO Jayesh Kulkarni will be showing off his LNP expertise in the Centre for Heart Lung Innovation (HLI) Seminar Series on June 2 at UBC.
Kevin An @ ASGCT 26th Annual Meeting
Catch the May 17 presentation by NTx Formulation Scientist Kevin An at the ASGCT 26th Annual Meeting.
Pieter Cullis honoured as the 19th D. Harold Copp Lecturer
NTx Co-Founder Dr. Pieter Cullis was honoured as the 19th D. Harold Copp Lecturer on 5 May.
Pieter Cullis speaks @ Gairdner event
NTx Co-Founder Dr. Pieter Cullis, delivers a keynote talk & participates in a panel at a Gairdner Award event on May 9.
CSO Jayesh Kulkarni @ ISI 2023 in Brazil
NTx CSO Dr. Jayesh Kulkarni will discuss next-gen LNPs on a panel at the Institute of Technology in Immunobiology (ISI) 2023 in Brazil.
NTx @ RNA Leaders Europe Congress 2023
We'll be there! NTx is a proud co-sponsor of RNA Leaders Europe Congress (Basel, 15-16 March).
Particle Works partners with NTx UK for LNP development
Particle Works is collaborating with NTx UK to reduce the time and costs associated with the screening of novel LNP formulations for use in nucleic acid delivery applications.
NTx CSO Dr Jayesh Kulkarni will be talking at the LNP Immunogenicity & Toxicity Summit in Boston on Dec 8.
CEO Dominik Witzigmann @ BioFIT 2022
NTx CEO Dominik Witzigmann will be part of the panel discussion focused on the potential of mRNA technology as a therapeutic platform at the BioFIT Event 2022 Conference in Strasbourg.
CBO Don Enns @ Blakes Breakfast Series
Our Chief Business Officer Don Enns is an invited speaker to the Blakes Breakfast Series, on Wednesday 16 Nov.
Innovate BC supports NanoVation project to improve mRNA stability and production for vaccines
A project being led by NTx and Dr. Eric Jan of UBC has been awarded the maximum funding allotment available through BC Innovate's Ignite program.
Co-Founder Dr. Pieter Cullis wins 2022 Bloom Burton Award
The Board Chair and Co-Founder of NTx, Dr. Pieter Cullis, has received another honour in recognition of his pioneering work on the development of LNP delivery systems.
Arpan Desai @ LNP Development Europe Summit
Arpan Desai, Managing Director of NTx's UK GENErator, will be speaking at Lipid Nanoparticles Development Europe Summit.
CSO Jayesh Kulkarni @ MilliporeSigma virtual mRNA Symposium
Hear our CSO Jayesh Kulkarni discuss the design of LNPs for extrahepatic gene therapy at this Oct 11 virtual mRNA Symposium organized by MilliporeSigma.
NanoVation Therapeutics™ & Baseimmune announce innovative mRNA vaccine collaboration
Baseimmune™ and NanoVation Therapeutics™ (NTx) today announced their preclinical partnership program to accelerate the development of more effective vaccines against a range of infectious diseases.
NTx scientists publish in European J. of Pharm. Sciences
The co-authors detail their efforts to broaden the application of LNPs in targeting non-hepatic tissues by developing LNP-based RNA therapies for the respiratory tract.
NTx’s Dr. Arpan Desai publishes in Journal of Controlled Release
NanoVation’s Dr. Arpan Desai (UK) and co-authors describe the systematic optimisation of lipid-peptide nanocomplexes for the delivery of mRNA in two murine cancer cell types...
NTx’s Drs. Jayesh Kulkarni & Pieter Cullis publish in Langmuir
Co-authored by NanoVation’s Drs Jayesh Kulkarni & Pieter Cullis, this article develops a straightforward “bottom-up” approach to manufacture drug-loaded LNP-GNP systems.
NTx’s Drs. Fariba Saadati & Marco Ciufolini publish in Chemistry: A European Journal
This paper describes a synthesis of ALC-0315 by a sequence that more than doubles the overall yield relative to the published one, and that employs much cleaner reactions...
NTx’s Dr. Jayesh Kulkarni publishes in Plant Cell on monolignol export by diffusion
NTx's Dr. Jayesh Kulkarni co-authored this article in The Plant Cell on monolignol export by diffusion down a polymerization-induced concentration gradient.
CEO Dominik Witzigmann Co-Organizes CRS Symposium on LNP-RNA Therapeutics
NanoVation Therapeutics™ CEO & Co-Founder Dr. Dominik Witzigmann co-organized a 2-day virtual symposium on “LNP-RNA Therapeutics: Beyond COVID.”
Co-Founder Dr. Pieter Cullis wins Gairdner Award
NanoVation™ Co-Founder Dr. Pieter Cullis and his colleagues Katalin Karikó and Drew Weissman were awarded the Gairdner International Award “for their pioneering work developing nucleoside-modified mRNA and LNP drug delivery..."
NTx UK’s Dr. Arpan Desai publishes in SLAS Discovery
Dr. Arpan Desai co-authored this article on arrayed CRISPR screening to identify novel targets that enhance the productive delivery of mRNA by MC3-based LNPs.
NanoVation Therapeutics™ launches UK hub
NanoVation Therapeutics™ (NTx) is pleased to announce the expansion of its global gene therapy builder with the launch of its first GENErator™, NanoVationTx™ UK.
LNP Formulation & Process Development Summit
Come hear CSO Dr. Jayesh Kulkarni discuss the composition of LNPs with respect to their efficacy & function.
NTx scientists publish on using anionic LNPs to deliver mRNA in Advanced Materials
NTx's Drs. Frederick Campbell, Dominik Witzigmann and Pieter Cullis co-authored this article on anionic LNPs that preferentially deliver mRNA to the hepatic reticuloendothelial system.
NTx @ RNA Leaders World Congress 2022
NanoVation Therapeutics is both a sponsor and speaker at the RNA leaders world Congress happening March 16-17th 2022.
NTx @ OBIO 2022
Looking for for the next big hit to invest in in the biotech industry? Come listen to us pitch at the Ontario Bioscience Innovation Organization (OBIO) Investment Summit.
NTx’s Dr. Arpan Desai publishes in Nanoscale on developing a high-throughput LNP screening platform
NTx UK's Dr. Arpan Desai co-authored this artilce on developing a high-throughput platform for screening LNPs for mRNA delivery.
Dr. Arpan Desai publishes in SMALL on mechanistic studies of an automated LNP
Dr. Arpan Desai co-authored this artlce in SMALL on how mechanistic studies of an automated LNP revealed pharmaceutical properties associated with enhanced mRNA functional delivery.
NTx @ 9th mRNA Health Conference
NTx CEO Dr. Witzigmann presents in-person at the 9th International mRNA Health Conference in Berlin, Germany
NTx CEO Dr. Witzigmann gives invited talk at 3rd CRIG Industrial Partnering Event
NTx CEO Dr. Witzigmann delivered an invited talk during “Bringing drug delivery to the market” session of the 3rd CRIG Industrial Partnering Event.
NTx CEO Dr. Witzigmann presents @ International Symposium on Phospholipids
NTx CEO Dr. Witzigmann spoke at the International Symposium on Phospholipids in Pharmaceutical Research 2021.
NTx scientists publish in American J. of Physiol.
NTx's Drs. Anthony Tam, Jayesh Kulkarni, Dominik Witzigmann and Pieter R Cullis co-authored this paper on FAM13A as potential therapeutic target in modulating airway tissue remodeling in COPD.
CIHR highlights role of LNPs in COVID vaccines
The Canadian Institutes of Health Research (CIHR) has highlighted the role of NTx's Dr. Pieter Cullis in developing the LNPs that have enabled mRNA vaccine development.
NTx Co-Founder Dr. Pieter Cullis interviewed on CBC
Listen to Dr. Pieter R Cullis on CBC radio's Quirks & Quarks, discussing the role of his work in the COVID 19 vaccines.
NTx Workshop @ CRS 2021
NanoVation co-organizes an Industry Educational Workshop as part of the Controlled Release Society Annual Meeting.
NTx’s Dr. Jayesh Kulkarni publishes on scalable production of LNPs containing Amphotericin B
Dr. Jayesh Kulkarni co-authored this paper in Langmuir on the scalable production of LNPs containing Amphotericin B.
NTx Co-Founders publish on current landscape of nucleic acid therapeutics
Three NTx co-founders wrote this review article in Nature Nanotechnology on the current landscape of nucleic acid therapeutics.
NTx scientists publish in SMALL on optimized LNPs for red light-triggered drug release
NTx's Drs Dominik Witzigmann and Pieter R Cullis published this article in Small, on optimized photoactivatable LNPs to enable red light-triggered drug release.